• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    iMDx to Participate in NYC Investment Conferences September 8 - 11

    8/26/25 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IMDX alert in real time by email

    NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (NASDAQ:IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below:

    Event: H.C. Wainwright 27th Annual Global Investment Conference

    Date: September 8 – 9, 2025

    Location: In-person at the Lotte New York Palace Hotel and virtual

    Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetings

    Link to live and replay: Click here

    Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9)

    Date: September 11, 2025

    Location: In-person at the Yale Club of New York City

    Format: One-on-one meetings



    Investors wishing to participate are encouraged to reach out to their H.C. Wainwright or Lake Street sales representatives.

    About Insight Molecular Diagnostics, Inc.

    Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.Insight Molecular Diagnostics.com/ for more information.

    GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

    Investor Contact: 

    Doug Farrell 

    LifeSci Advisors LLC 

    [email protected]



    Primary Logo

    Get the next $IMDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMDX
    SEC Filings

    View All

    Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    9/19/25 4:05:48 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-8 filed by Insight Molecular Diagnostics Inc.

    S-8 - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    8/18/25 4:06:09 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.

    10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    8/11/25 4:11:34 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

    IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced attendance at two key industry conferences where it will discuss its GraftAssure™ technology, including its clinical kitted test under development. At the 23rd IATDMCT annual meeting, which is being held September 21st to 24t

    9/24/25 7:05:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

    5,000-participant, multi-center registry supported by iMDx's central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA)Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one scoreRegistry expected to assess utility of "the Berlin protocol" of accelerated testing for certain patients at high risk for organ rejectionRegistry program is incremental, complementary and symbiotic to iMDx "kitted strategy" NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSW

    9/8/25 7:15:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

    iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (NASDAQ:IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, the official clinical trial listing now names 10 leading transplant centers, up from five previously. The ongoing clinical trial is an important step toward obtaining regulatory authorization to deliver an organ transplant r

    9/8/25 7:00:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Financials

    Live finance-specific insights

    View All

    iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

    NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (NASDAQ:IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's investor relations website at https://investors.imdxinc.com/. 10th Annual Needham Virtual MedTech & Diagnostics 1x1

    8/4/25 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

    iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the World Transplant CongressNational Principal Investigator and Key Opinion Leader call Friday, August 15th at 4 p.m. ET to discuss GraftAssureTM - branded family of assays NASHVILLE, Tenn., July 30, 2025 (GLOBE NEWSWIRE) -- Insight Molecular

    7/30/25 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

    Study indicates iMDx flagship technology's equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx's digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (NASDAQ:IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-t

    6/23/25 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care